• About Us
    • Overview
    • Education
    • Mission & History
    • Board of Directors
    • The Campus
    • Careers
  • Our Achievements
    • Overview
    • Cancer
    • Technology
    • Education
    • Our Planet
    • Health & Medicine
    • Physical World
  • Get Involved
    • Overview
    • Partners in Science
    • Estate & Planned Giving
    • Attend an Event
    • Gift Opportunities
  • News & Media
    • Overview
    • News & Media Archive
    • Coronavirus
    • Feature Stories
    • News Releases
    • In The News
    • Video Gallery
    • Ad Campaigns
    • Celebrating Great Minds
  • Blog
  • Contact
  • Donate
Donate
Donate
About Us tri
About Us Overview
  • Education
  • Mission & History
  • Board of Directors
  • The Campus
  • Careers
About Us

Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.

Our Achievements tri
Our Achievements Overview
  • Cancer
  • Technology
  • Education
  • Our Planet
  • Health & Medicine
  • Physical World
Our Achievements

The Weizmann Institute’s fundamental research has led to discoveries and applications with a major impact on the scientific community and on the quality of life for millions worldwide.

Get Involved tri
Get Involved Overview
  • Partners in Science
  • Estate & Planned Giving
  • Attend an Event
  • Gift Opportunities
Get Involved

Join a community of dedicated people who share the Weizmann Institute’s commitment to shaping a better world through science.

News & Media tri
News & Media Overview
  • News & Media Archive
  • Coronavirus
  • Feature Stories
  • News Releases
  • In The News
  • Video Gallery
  • Ad Campaigns
  • Celebrating Great Minds
News & Media

Learn about the Weizmann Institute’s latest groundbreaking discoveries and the American Committee’s activities across the country.

Blog tri
  • The Curiosity Review
Blog

Popular science for the curious-minded: The Curiosity Review brings discovery to life.

Contact

Search Results

  • SEARCH BY KEYWORD
  • SEARCH BY TAG
View Articles by Tag:
  • View Articles by Tag
  • Algorithims (6)
  • Alternative energy (27)
  • Alzheimers (44)
  • Archaeology (37)
  • Artificial intelligence (20)
  • Astrophysics (108)
  • Autism (22)
  • Awards (119)
  • Bacteria (107)
  • Behavior (9)
  • Biochemistry (101)
  • Biofuel (7)
  • Biology (309)
  • Biomolecular sciences (7)
  • Blood (43)
  • Brain (175)
  • Cancer (163)
  • Cancer treatment (127)
  • Central nervous system (9)
  • Chemistry (78)
  • Children (7)
  • Circadian clock (1)
  • Climate change (73)
  • Clinical trials (40)
  • Collaborations (19)
  • Community (279)
  • Computers (73)
  • Copaxone (12)
  • Coronavirus (7)
  • Culture (359)
  • Diabetes (32)
  • Earth (74)
  • Education (157)
  • Environment (92)
  • Enzymes (29)
  • Evolution (89)
  • Fertility (20)
  • Fungus (4)
  • Genetics (109)
  • Genomics (3)
  • Heart (5)
  • Heart disease (3)
  • Humanity (83)
  • Immune system (149)
  • Immunology (10)
  • Immunotherapy (34)
  • Inflammation (19)
  • Leadership (114)
  • Leukemia (12)
  • Materials (44)
  • Mathematics (62)
  • Medicine (84)
  • Memory (39)
  • Mental health (58)
  • Metabolism (51)
  • Microbiology (2)
  • Microbiome (10)
  • Molecular cell biology (9)
  • Molecular genetics (61)
  • Multiple sclerosis (12)
  • Nanoscience (33)
  • Nature (4)
  • Neurobiology (2)
  • Neuroscience (207)
  • Nutrition (72)
  • Optics (34)
  • Organs (11)
  • Parkinsons (11)
  • Personalized medicine (5)
  • Philanthropy (148)
  • Physics (139)
  • Plants (56)
  • Proteins (96)
  • Quantum computer (3)
  • Quantum physics (2)
  • Quantum theory (34)
  • Robots (8)
  • Security (21)
  • Senses (115)
  • Sensors (8)
  • Smoking (1)
  • Solar power (19)
  • Space (110)
  • Stem cells (49)
  • Technology (206)
  • Vaccine (40)
  • Virus (135)
  • Water (40)
  • Weather (1)
  • Women (115)
  • World hunger (17)
Filter by Time:
  • All
  • Past Day
  • Past Week
  • Past Month
  • Past Year
  • Past Three Years
Clear Filters

83 results for Medicine

The Israel-Inspired Revolution in Arthritis Treatment
The Israel-Inspired Revolution in Arthritis Treatment

https://weizmann-usa.org/news-media/in-the-news/the-israel-inspired-revolution-in-arthritis-treatment/

Jul 03, 2013... Israel has provided the global drug development pipeline with many well–known internationally successful medications including Copaxone, Rebif, Exelon, Doxil, Azilect and Gonal. In fact there is yet another well–known drug that is not very often associated with Israel – Enbrel, for the treatment of inflammatory diseases and probably the most successful Israeli drug that you do not recognize as Israeli.

TAGS: Medicine, Inflammation

What the Weizmann Institute Is Doing to Fight Breast Cancer
What the Weizmann Institute Is Doing to Fight Breast Cancer

https://weizmann-usa.org/news-media/feature-stories/what-the-weizmann-institute-is-doing-to-fight-breast-cancer/

Oct 11, 2011... October is National Breast Cancer Awareness Month
October is National Breast Cancer Awareness Month, bringing critical attention to what is today the most common form of cancer in women, apart from skin cancers. Most breast cancers begin in the cells that line the milk ducts (ductal carcinoma) or in the milk-producing glands (lobular carcinoma). At the Weizmann Institute of Science, researchers are studying genes and hormones that play a role in these cancers and are developing better diagnostic tools and treatments. Some examples of this research are presented below.

TAGS: Women, Medicine, Cancer

November is American Diabetes Month
November is American Diabetes Month

https://weizmann-usa.org/news-media/feature-stories/november-is-american-diabetes-month/

Nov 01, 2017... As we enter a time of year abundant with food-centric holidays and gatherings, it can be helpful to pause for a moment to think about how we eat – and how much. We all know that overeating and consuming unhealthy foods often leads to obesity, which often leads to diabetes – frequently as part of metabolic syndrome, a cluster of conditions comprised of four interrelated illnesses: obesity, diabetes, heart disease, and high blood pressure. But despite this awareness, diabetes rates keep soaring worldwide. In the U.S. alone, reports the American Diabetes Association, more than 29 million of us have the disease – that’s 1 in 11 people. Even more alarming is that 86 million Americans have prediabetes, meaning that 1 in 3 are on the verge of becoming diabetic.

TAGS: Medicine, Biochemistry, Diabetes, Metabolism

“My Intuition Says Teva Will Get Out of This”
“My Intuition Says Teva Will Get Out of This”

https://weizmann-usa.org/news-media/in-the-news/my-intuition-says-teva-will-get-out-of-this/

Oct 09, 2017... Prof. Michael Sela Photo: Eyal Izhar
“My intuition tells me that Teva will extricate itself,” Professor Michael Sela, who, together with Ruth Arnon and Deborah Teitelbaum, developed Teva’s blockbuster multiple sclerosis treatment Copaxone at the Weizmann Institute, told “Globes” yesterday.
It was Sela’s close friendship with the late Eli Hurvitz, Teva’s legendary CEO, that brought Copaxone to Teva and made the company what it is today. Former Teva CFO, and currently a director of the company, Dan Suesskind has related in the past how Sela spoke to Hurvitz about a potential drug, COP-1, which eventually became Copaxone. “Fortunately, Teva was allowed to look at the drug file for just $50,000. Who knows, maybe if thrifty Eli had been offered the file for $500,000, Copaxone would never have seen the light of day,” Suesskind said.

TAGS: Technology, Medicine, Multiple sclerosis, Copaxone

Best People, Best Science
Best People, Best Science

https://weizmann-usa.org/news-media/video-gallery/best-people-best-science/

Jul 06, 2016... The Weizmann Institute's most important asset is its people. That's why the Institute is committed to recruiting and nurturing some of the world's brightest young researchers. Here, six impressive new scientists – Drs. Ronen Eldan, Ofer Firstenberg, Yifat Merbl, Neta Regev-Rudzki, Nir London, and Efi Efrati – share how the Institute is helping them make breakthroughs in areas ranging from malaria to optics.

TAGS: Culture, Community, Chemistry, Medicine, Cancer, Biology, Physics, Optics, Mathematics

Bacteria Alert by Scientist
Bacteria Alert by Scientist

https://weizmann-usa.org/news-media/in-the-news/bacteria-alert-by-scientist/

Dec 01, 2017... The Israeli crystallographer, who shared the chemistry Nobel with Venkatraman Ramakrishnan and Thomas A. Steitz in 2009 for her work on ribosome, was delivering the 79th Foundation Day lecture on “Next Generation Environmental Friendly Antibiotics” at Bose Institute on Thursday.
“Resistance to antibiotics is a real big problem to modern medicine. Multi-drug resistance has developed not because we use antibiotics, but because bacteria has evolved and uses mechanisms against other bacteria in their fight for resources,” Yonath said.

TAGS: Genetics, Medicine, Bacteria

Teva Pursues First Type 1 Diabetes Treatment Since Insulin
Teva Pursues First Type 1 Diabetes Treatment Since Insulin

https://weizmann-usa.org/news-media/in-the-news/teva-pursues-first-type-1-diabetes-treatment-since-insulin/

Dec 20, 2011... Teva Pharmaceutical Industries Ltd., the world’s largest generic-drug maker, is seeking to transform a compound once rejected by Sanofi into the first treatment to succeed insulin for Type 1 diabetes.
The therapy, DiaPep277, is made from a human protein that stops the immune system from destroying the pancreatic beta cells that secrete insulin, a hormone needed to convert sugar, starches and other food into energy. The drug also helps control sugar levels in the blood, a late-stage study showed last month.

TAGS: Medicine, Diabetes, Clinical trials

South Korea Firm to Invest $10m in Weizmann Scientists’ Anti-Cancer Drug
South Korea Firm to Invest $10m in Weizmann Scientists’ Anti-Cancer Drug

https://weizmann-usa.org/news-media/in-the-news/south-korea-firm-to-invest-10m-in-weizmann-scientists-anti-cancer-drug/

Mar 20, 2019... Yeda CEO Gil Granot-Mayer (left to right) BioLeaders CEO, Dr. Young-Chul Park and Weizmann Institute Vice President for Technology Transfer Prof. Mordechai Sheves (Weizmann Institute of Science)
An anti-cancer therapy that has been developed by scientists at the Weizmann Institute of Technology will get a $10 million investment from a South Korean biopharmaceutical company that is traded on the Korea Stock Exchange. This is the Korean firm’s first investment in an Israeli venture, the Weizmann Institute said in a statement.

TAGS: Technology, Community, Medicine, Biology

The Origins of Blood and Lymphatic Vessels and the Hope for New Therapies
The Origins of Blood and Lymphatic Vessels and the Hope for New Therapies

https://weizmann-usa.org/news-media/feature-stories/the-origins-of-blood-and-lymphatic-vessels-and-the-hope-for-new-therapies/

Oct 11, 2011... “I believe there is real magic in the way thatembryos develop. I’ve been studying them for almost 15 years and Ihaven’t stopped being amazed,” says Dr. Karina Yaniv of the WeizmannInstitute of Science’s Department of Biological Regulation.
Dr. Yaniv focuses on examining how blood and lymphatic vessels formduring embryonic development. Her research may, in the future, lead tonew therapies for heart disease, stroke, cancer, and other illnesses. “Ithink it’s imperative for us to learn how to manipulate vessel growth,”she says. “Sometimes we want to encourage vessel growth and sometimeswe want to stop it.”

TAGS: Women, Medicine, Cancer, Biology, Blood

Weizmann Institute of Science Announces Visiting Scientist Agreement with Pfizer Inc.
Weizmann Institute of Science Announces Visiting Scientist Agreement with Pfizer Inc.

https://weizmann-usa.org/news-media/news-releases/weizmann-institute-of-science-announces-visiting-scientist-agreement-with-pfizer-inc/

Jun 06, 2016... Dr. Bruce Lasker of Pfizer and Dr. Berta Strulovici, head of the G-INCPM, on the Weizmann campus
REHOVOT, ISRAEL—June 6, 2016—The Weizmann Institute of Science in Rehovot, Israel, and Yeda Research and Development Co., Ltd., its commercial arm, announced this week that they have entered a multi-year arrangement with Pfizer Inc. The arrangement will entail collaboration at the newly established National Drug Discovery Institute (DDI) in the Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM), which is part of the Weizmann Institute and located on its campus. Pfizer will be supporting the G-INCPM by placing a Pfizer medicinal chemist (rotating on a yearly basis) at the Institute to assist with advancing target selection and high-throughput screening, as well as leading development campaigns for programs that enter the DDI. If projects of mutual interest – those that hold promise in addressing unmet medical needs – are identified, Pfizer and Yeda will evaluate the potential for research and development agreements.

TAGS: Community, Medicine

First 1 2 3 4 5 6 7 8 9 Last
Back Next
SHARE

Our Achievements

Learn more about remarkable Weizmann Institute achievements that are enhancing and transforming our lives.

Learn More

Support Our Flagship Projects

Help us accelerate exciting initiatives in three forward-looking fields: neuroscience, physics, and artificial intelligence.

Donate Now

Newsletter

Get the latest news and breakthroughs from the Weizmann Institute of Science.

About Us
  • Education
  • Mission & History
  • Board of Directors
  • The Campus
  • Careers
Our Achievements
  • Cancer
  • Technology
  • Education
  • Our Planet
  • Health & Medicine
  • Physical World
Get Involved
  • Partners in Science
  • Estate & Planned Giving
  • Attend an Event
  • Gift Opportunities
News & Media Blog: Curiosity Review Donate Now Contact Us
Privacy Policy Gift Acceptance Policy Financial Information

©2023 American Committee for the Weizmann Institute of Science

Charity Navigator

FOR THE FOURTH CONSECUTIVE YEAR

Platinum Transparency 2023